Combined effect of Levothyroxine and Oral Hypoglycemic agents on blood glucose level in hypothyroidism patients- A Prospective Observational Study

Anandkumar S.*, Shanmugapandiyan P.
Department of Pharmacy, Ponnaiyah Ramajayam Institute of Science and Technology, (PRIST University), Thanjavur-613403, Tamilnadu, India

ABSTRACT
This study was aimed to evaluate the effect of levothyroxine combination therapy on blood glucose level in hypothyroidism patients. The Study was carried out in a private hospital at Tiruchengode as prospective observationally. Patients who were under the management of thyroid disorder and diabetes mellitus for 1 year period was screened and selected for the study. Effect of levothyroxine on blood glucose level and using a Mini mental state examination questionnaire their cognitive skills were also assessed. Independent sample t’ test was used to compare the blood glucose level and complication of the management. There were 42 patients were included in the study and the patients who were on Levothyroxine and Glimepride with Metformin labeled as Group 1 and Glimepride with Metformin alone was labeled as Group 2. Glimepride with metformin therapy shows greater percentage of blood glucose level reduction and significant p<0.05 cognitive impairment was found in the combination therapy. Diabetes mellitus management with levothyroxine and glimepride with metformin has an association on the managing blood glucose level. Efficient management of blood glucose level was obtained with glimepride with metformin alone. Cognition impairment was high in the combination therapy of levothyroxine and glimepride with metformin.

INTRODUCTION
Hypothyroidism is the metabolic disorder of the thyroid gland. During hypothyroidism clinical condition thyroid gland not produce sufficient amount of thyroid hormone for the metabolic need of the body. Human body has the largest endocrine gland is known as thyroid gland it present in the neck that produce thyroid hormone. This weighs about 15-20 gm in human. Thyroid gland consists of two glands both the glands secrete thyroid hormone. The gland is composed of spherical follicles that secrete and stores thick, colloid, sticky protein material. Para follicular cells are present between the follicles, which secretes hormone calcitonin. This gland receives the blood from the inferior thyroid artery for the normal thyroid functions. Hypothyroidism requires proper management and improperly treated hypothyroidism resulting in metabolic management difficulty like diabetes mellitus (Kostoglou-Athanassiou and Ntalles, 2010).

Hypothyroidism and its management is the risk factor for diabetes mellitus. On other hand thyroid replacement therapy leads to disruptions of carbohydrate. Thyroid replacement therapy does not alter glucose levels but some time it raise the blood glucose level faster than the normal. Excessive thyroid hormones lead to increase the glucose
absorption in gastro intestinal tract and also result-
ing in insulin resistance and insulin degradation and resulting in diabetic complications (Porterfield, 2000).

Thyroid hormone leads to increase glucose absorp-
tion from peripherals and increase the glycogen pro-
ductions resulting in difficulty in blood glucose man-
gement in diabetes mellitus patients. However hypo-
thyroidism also managed with thyroid hormone that resulting in additional diabetic complic-
ations like diabetic ketoacidosis and insulin resis-
tance (Hansen et al., 2015). Patients with hypothy-
roidism and diabetes mellitus have risk of developing obesity and high dose was required for the dia-
betic management (McConnell, 1999; Samuels et al., 2003; Adhimoolam and Arulmozhi, 2016).

So our study planned to compare and check the ther-
apy of Glimepride 2mg and Metformin 500mg ver-
sus Levothyroxine 50mcg and Glimepride 2mg with Metformin 500mg combination therapy in blood glucose level and cognitive skills.

MATERIALS AND METHODS

Study design and sample

A prospective observational study was conducted in a Vivekananda Medical Care Hospital at Tiruchenge-
de. The patients with hypothyroidism and dia-
betes mellitus with age group of 30 to 60 were included in the study.

Sampling technique

Simple random sampling technique was employed in this study (Lemeshow et al., 1990). According to this technique a sample group of 90 patients selected have an equal opportunity. According to the inclusive criteria of this study totally 42 patients were final participants until completion of the work. Chronically ill patients, Patients with multi-
ple Drug therapy, improper availability of patients are not included in our study. Institutional Eth-
ical committee approval was obtained from the Vivekananda Medical Care Hospital. Patients consent was obtained from the participants.

Totally 90 patients were included for our study from that proper follow up was from 42 patients so the study was performed with the same study populations. And the collected patients were separated into two groups. Patients were on the Levothyrox-
ine 50 mcg with Glimepride 2mg with Metformin 500mg therapy was labeled as (Group 1), Patients were on the Glimepride 2mg with Metformin 500mg therapy was labeled as (Group 2) as mention in Table 1. Blood glucose level and cognition was measured with suitable technique. Blood glucose level was measured by UV-Vis (Ultraviolet-Visible) method and Cognitive functions screening was measured with the help of Mini Mental State Exami-

nations (MMSE) scale (Tombaugh and McIntyre, 1992). Score were calculated for the both the groups and data were compared and risk of cognition was also assessed in this study.

Group 1 was checked with Fasting Blood Glucose, Postprandial Blood Glucose initial phase and after 1 year of therapy for the both the groups. Group 2 was checked with Fasting Blood Glucose, Postpran-
dial Blood Glucose and after 1 year of therapy for the both the groups. And cognition was analyzed for both the groups after 1 year of drug therapy and the mean was compared.

Data collection tool

Data were collected through specially designed data entry format in order to collect the details of the Patient details including name, age, sex, known allergy, educational status, I.P No/O.P,No. Fasting Blood Glucose, Post Prandial Blood Glucose, Mini mental state examinations (MMSE) score and drugs treatment details were collected.

RESULTS AND DISCUSSION

Comparison on blood glucose level of both groups

In the group 1 before and after 1 year of manage-
ment with Levothyroxine 50 mcg and Glimepride 2mg with Metformin 500mg therapy and the group 2 before and after 1 year of management of Glimepride 2mg with Metformin 500mg therapy shows significant reduction of Blood Glucose level. On comparison of both the groups does not show significant Blood Glucose Level reduction as mention in Table 2. Our study coincidence with similar study conducted on oral hypoglycemic agents and reported that metformin with glimepride have a sign-
ificant glycemic control and between blood glucose level (Zhu et al, 2013).

On the percentage of reduction in Blood Glu-
cose Level between both the groups identified that Glimepride 2mg with Metformin 500mg shows greater percentage of reduction of Blood Glucose Level when compared to combination therapy of Levothyroxine 50mcg Glimepride 2mg with Met-
formin 500mg therapy. Our results shows that effective management of Blood Glucose Level was attain with the Glimepride 2mg with Metformin 500mg and also it proves that diabetes mellitus risk was increased significantly on combination therapy of Levothyroxine 50mcg Glimepride with Metformin 20mg as given in Table 3. Our study similar to the

© International Journal of Research in Pharmaceutical Sciences 1871
Table 1: Demographic Characteristics of Patients

<table>
<thead>
<tr>
<th>Variables</th>
<th>Levothyroxine 50 mcg and Glimepride 2 mg with Metformin 500 mg (n=21)</th>
<th>Glimepride 2 mg with Metformin 500 mg (n=21)</th>
<th>Study Populations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Distribution of age</td>
<td>04 02 06</td>
<td>11 09 20</td>
<td>06 20 16</td>
</tr>
<tr>
<td>30-40</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>41-50</td>
<td>06</td>
<td></td>
<td></td>
</tr>
<tr>
<td>51-60</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td>Male 08 09 17</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female 13 12 25</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2: Mean Blood glucose level of Group 1 & Group 2

<table>
<thead>
<tr>
<th>Parameter (mg/dL)</th>
<th>Levothyroxine 50 mcg and Glimepride 2 mg with Metformin 500 mg</th>
<th>Glimepride 2 mg with Metformin 500 mg</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting Glucose Level</td>
<td>137.43±18.44</td>
<td>129.27±6.37</td>
<td>P&gt;0.05</td>
</tr>
<tr>
<td>Post Prandial Glucose level</td>
<td>154.86±18.59</td>
<td>169.73±4.651</td>
<td></td>
</tr>
</tbody>
</table>

Numbers indicate mean ± SD
P value of Student ‘t’ test (Group 1 Vs Group2)
Significant P value (<0.05) in bold face.

Table 3: Percentage of reductions in blood glucose between group 1 & group 2

<table>
<thead>
<tr>
<th>Parameter (mg/dL)</th>
<th>Levothyroxine 50 mcg and Glimepride 2 mg with Metformin 500 mg</th>
<th>Glimepride 2 mg with Metformin 500 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting Blood Glucose</td>
<td>19</td>
<td>62</td>
</tr>
<tr>
<td>Post Prandial Blood Glucose</td>
<td>28</td>
<td>33</td>
</tr>
</tbody>
</table>

Table 4: Mini mental state Examination score between group 1 & 2

<table>
<thead>
<tr>
<th>Drugs</th>
<th>MMSE Score (mean±SD)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levothyroxine 50 mcg and Glimepride 2 mg with Metformin 500 mg</td>
<td>13.43±2.3</td>
<td>P &lt; 0.05</td>
</tr>
<tr>
<td>Glimepride 2 mg with Metformin 500 mg</td>
<td>24.1±2.99</td>
<td></td>
</tr>
</tbody>
</table>

P value of Student ‘t’ test (Group 1 Vs Group 2)
Significant P value (<0.05) in bold face

study concluded that the better glycemic control was attained in the diabetic mellitus patients alone (Kim et al., 2014).

Comparison on cognition for both groups

MMSE was also calculated using the tools initial phase and after 1 year of therapy and its mean and standard deviation and its significance was identified that the patients with hypothyroidism and diabetes mellitus combined management patients have sever cognitive impairment (Biessels and Despa, 2018). And our study state that increased in age groups resulting in obliviously decline in cognitive functions (Galea and Woodward, 2005).

Central nervous system functions was declined with the management of hypothyroidism patients with levothyroxine on other hand the patients with diabetic management alone not have any central nevous system dysfuntions. Diabetes management...
alone not have cognitive impairment (Herath et al., 2016).

When compared to Glimepride 2mg with Metformin 500mg therapy (24.1±2.99) Levothyroxine 50mcg and Glimepride 2mg with Metformin 500mg (13.43±2.31) combination therapy leads to significant cognition impairment (p<0.05) as mention in the Table 4. On study upon diabetic patient’s population not have any cognitive decline throughout the study. On metformin drug therapy showed significant effects on cognitive functions. Diabetes mellitus patients have lesser cognitive impairment on compared to thyroid replacement therapy (Knouse and Safren, 2010).

CONCLUSION

Hypothyroidism management along with diabetes mellitus management has an association on the managing Blood Glucose Level. Efficient management of blood glucose level was attaining with Glimepride with Metformin therapy. And the same time cognition impairment was high in the combination therapy of Levothyroxine and Glimepride with Metformin compared to the therapy of Glimepride with Metformin.

ACKNOWLEDGEMENT

We would like to express our special thanks to the Director of PRIST, Thanjavur, Tamilnadu, India. And my heartfelt thanks to beloved Physician Dr.S.Arthanareeswaran, M.D, General Medicine Vivekananda Medical Care Hospital, Tiruchengode and the patients who supported for the study to complete.

REFERENCES


